Actions of the sodium channel inhibitor 202W92 on rat midbrain dopaminergic neurons

Synapse

Volumn 48, Issue 3, 2003, Pages 123-130

  Caputi, Luigi ^a,c   Hainsworth, Atticus ^b   Guatteo, Ezia ^a   Tozzi, Alessandro ^a   Stefani, Alessandro ^c   Spadoni, Francesca ^c   Leach, Michael ^d   Bernardi, Giorgio ^a,c   Mercuri, Nicola B ^a,c  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b DE MONTFORT UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF GREENWICH   (United Kingdom)

Author keywords

Firing discharge; Neuroprotection; Parkinson's disease; Sodium influx; Synaptic transmission

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 2,4 DIAMINO 6 (FLUOROMETHYL) 5 (2,3,5 TRICHLOROPHENYL)PYRIMIDINE; 202W92; 4 AMINOBUTYRIC ACID; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; GLUTAMIC ACID; ION CHANNEL; LAMOTRIGINE; RILUZOLE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; TETRODOTOXIN; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; MALE; MESENCEPHALON; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATCH CLAMP; PRIORITY JOURNAL; RAT; SYNAPTIC TRANSMISSION;

ACTION POTENTIALS; ANIMALS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY POSTSYNAPTIC POTENTIALS; MALE; MESENCEPHALON; NEURONS; ORGAN CULTURE TECHNIQUES; PATCH-CLAMP TECHNIQUES; PYRIMIDINES; RATS; RATS, WISTAR; SODIUM CHANNEL BLOCKERS; SYNAPTIC TRANSMISSION;

EID: 0344088446     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10195     Document Type: Article

References (44)

1. Andreasen M, Habliz JJ. 1992. Kinetic properties of a transient outward current in rat neocortical neurons. J Neurophysiol 66:1133-1142.
2. Barneoud P, Mazadier M, Miquet JM, Parmentier S, Dubedat P, Doble A, Boireau A. 1996. Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. Neuroscience 74:971-983.
3. Beal MF. 1992. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 31:119-130.
4. Benazzouz A, Boraud T, Dubedat P, Boireau A, Stutzmann JM, Gross C. 1995. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol 284:299-307.
5. Bezard E, Stutzmann JM, Imbert C, Boraud T, Boireau A, Gross CE. 1998. Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model. Eur J Pharmacol 356: 101-104.
6. Blandini F, Greenamyre JT. 1998. Prospects of glutamate antagonists in the therapy of Parkinson's disease. Fundam Clin Pharmacol 12:4-12.
7. Boireau A, Dubedat P, Bordier F, Imperato A, Moussaoui S. 2000. The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. Neuropharmacology 39:1016-1020.
8. Calabresi P, Centonze D, Marfia GA, Pisani A, Bernardi G. 1999. An in vitro electrophysiological study on the effects of phenytoin, lamotrigine and gabapentin on striatal neurons. Br J Pharmacol 126: 689-696.
9. Caputi L, Hainsworth AH, Lavaroni F, Leach MJ, McNaughton NCL, Mercuri NB, Randall AD, Spadoni F, Swan JH, Stefani A. 2001. Neuroprotective actions in vivo and electrophysiological actions in vitro of 202W92. Brain Res 919:259-268.
10. Carter AJ, Grauert M, Pschorn U, Bechtel WD, Bartmann-Lindholm C, Qu Y, Scheuer T, Catterall WA, Weiser T. 2000. Potent blockade of sodium channels and protection of brain tissue from ischemia by BIII 890 CL. Proc Natl Acad Sci USA 97:4944-4949.
11. Clare JJ, Tate SN, Nobbs M, Romanos MA. 2000. Voltage-gated sodium channels as therapeutic targets. Drug Discov Today 5:506-520.
12. Doble A. 1999. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 81:163-221.
13. Dunlap K, Luebke JI, Turner TJ. 1995. Exocytotic Ca2+ channels in mammalian central neurons. Trends Neurosci 18:89-98.
14. Fredriksson A, Palomo T, Archer T. 1999. Effects of co-administration of anticonvulsant and putative anticonvulsive agents and sub/suprathreshold doses of L-dopa upon motor behaviour of MPTP-treated mice. J Neural Transm 106:889-909.
15. Gotz ME, Kunig G, Riederer P, Youdim MB. 1994. Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 63:37-122.
16. Grace AA. 1991. Regulation of spontaneous activity and oscillatory spike firing in rat midbrain dopamine neurons recorded in vitro. Synapse 7:221-234.
17. Greenamyre JT, Eller RV, Zhang Z, Ovadia A, Kurlan R, Gash DM. 1994. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol 35:655-661.
18. Greenamyre JT, MacKenzie G, Peng TI, Stephans SE. 1999. Mitochondrial dysfunction in Parkinson's disease. Biochem Soc Symp 66:85-97.
19. Grillner P, Berretta N, Bernardi G, Svensson TH, Mercuri NB. 2000. Muscarinic receptors depress GABAergic synaptic transmission in rat midbrain dopamine neurons. Neuroscience 96:299-307.
20. Guatteo E, Mercuri NB, Bernardi G, Knopfel T. 1999. Group I metabotropic glutamate receptors mediate an inward current in rat substantia nigra dopamine neurons that is independent from calcium mobilization. J Neurophysiol 82:1974-1981.
21. Hainsworth AH, Stefani A, Calabresi P, Smith TW, Leach MJ. 2000. Sipatrigine (BW 619C89) is a neuroprotective agent and a sodium channel and calcium channel inhibitor. CNS Drug Rev 6:111-134.
22. Harris NC, Webb C, Greenfield SA. 1989. A possible pacemaker mechanism in pars compacta neurons of the guinea-pig substantia nigra revealed by various ion channel blocking agents. Neuroscience 31: 355-362.
23. Hassani OK, Mouroux M, Bohme GA, Stutzmann JM, Feger J. 2001. Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain. Mov Disord 16:1110-1114.
24. Iyadomi M, Iyadomi I, Kumamoto E, Tomokuni K, Yoshimura M. 2000. Presynaptic inhibition by baclofen of miniature EPSCs and IPSCs in substantia gelatinosa neurons of the adult rat spinal dorsal horn. Pain 85:385-393.
25. Jones-Humble SA, Morgan PF, Cooper BR. 1994. The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson's disease. Life Sci 54:245-252.
26. Kang Y, Kitai A. 1993. Calcium spike underlying rhythmic firing in dopaminergic neurons of the rat substantia nigra. Neurosci Res 18:195-207.
27. Kaur S, Starr M. 1996. Motor effects of lamotrigine in naive and dopamine-depleted mice. Eur J Pharmacol 304:1-6.
28. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P. 1991. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 206:297-300.
29. Lacey MG, Mercuri NB, North RA. 1987. Dopamine acts on D2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta. J Physiol 392:397-416.
30. Leach MJ, Lees G, Riddall DR. 1995. Lamotrigine: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. New York: Raven Press. p 861-869.
31. Loschmann PA, Eblen F, Wullner U, Wachtel H, Kockgether T. 1995. Lamotrigine has no antiparkinsonian activity in rat models of Parkinson's disease. Eur J Pharmacol 284:129-134.
32. Mercuri NB, Bonci A, Calabresi P, Stefani A, Bernardi G. 1995. Properties of the hyperpolarization-activated cation current Ih in rat midbrain dopaminergic neurons. Eur J Neurosci 7:462-469.
33. Mereu G, Costa E, Armstrong DM, Vicini S. 1991. Glutamate receptor subtypes mediate excitatory synaptic currents of dopamine neurons in midbrain slices. J Neurosci 11:1359-1366.
34. Nedergard S, Greenfield SA. 1992. Sub-populations of pars compacta neurons in the substantia nigra: the significance of qualitatively and quantitatively distinct conductances. Neuroscience 48:423-437.
35. Pollard D, Carter K, Chapman A, Nobbs MS. 1998. Chiral phenylpyrimidines as anti-ischaemic agents. In: 15th EFMC International Symposium on Medicinal Chemistry, Edinburgh. p P195.
36. Shindou T, Mori A, Kase H, Ichimura M. 2001. Adenosine A(2A) receptor enhances GABA(A)-mediated IPSCs in the rat globus pallidus. J Physiol 532:423-434.
37. Shinotoh H, Vingerhoets FJ, Lee CS, Uitti RJ, Schulzer M, Calne DB, Tsui J. 1997. Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study. Neurology 48:1282-1285.
38. Starr MS, Starr BS, Kaur S. 1997. Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease. Neurosci Biobehav Rev 21:437-446.
39. Stefani A, Spadoni F, Siniscalchi A, Bernardi G. 1996. Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. Eur J Pharmacol 307:113-116.
40. Stefani A, Spadoni F, Bernardi G. 1997. Differential inhibition by riluzole, lamotrigine and phenytoin ofsodium and calcium currents in cortical neurons: implications for neuroprotective strategies. Exp Neurol 147:115-122.
41. Urenjak J, Obrenovitch TP. 1996. Pharmacological modification of voltage-gated Na+ channels: a rational and effective strategy against ischemic brain damage. Pharmacol Rev 48:21-67.
42. Wilson CJ, Callaway JC. 2000. Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J Neurophysiol 83:3084-3100.
43. Xie XM, Lancaster B, Peakman T, Garthwaite J. 1995. Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na+ channels and with native Na+ channels in rat hippocampal neurones. Pfleugers Arch 430:437-446.
44. Zipp F, Burklin F, Stecker K, Baas H, Fischer PA. 1995. Lamotrigine in Parkinson's disease - a double blind study. J Neural Transm Park Dis Dement Sect 10:199-206.